Sentiment-Signal
Score-Verlauf (90 Tage)
Stammdaten
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patients with Rett syndrome; Phase II clinical trial for the treatment of Parkinson's disease; and preclinical clinical trials to treat epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. The company's drug candidate also comprises ANAVEX 3-71, which is in Phase I clinical trial for the treatment of frontotemporal dementia and other dementia indications; and preclinical clinical trials for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's diseases. Its preclinical drug candidates include ANAVEX 1-41, a sigma-1 receptor agonist for the treatment of depression, stroke, Parkinson's, and Alzheimer's diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
Unternehmen & Branche
| Name | ANAVEX LIFE SCIENCES CORP. |
|---|---|
| Ticker | AVXL |
| CIK | 0001314052 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 302,6 Mio. USD |
| Beta | 1,18 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-Q | -5,681,000 | -0.06 | 132,989,000 | 126,618,000 | |
| 2025-09-30 | 10-K | -46,377,000 | -0.54 | 103,815,000 | 94,869,000 | |
| 2025-06-30 | 10-Q | -13,243,000 | -0.16 | 102,432,000 | 90,958,000 | |
| 2025-03-31 | 10-Q | -11,196,000 | -0.13 | 117,139,000 | 99,758,000 | |
| 2024-12-31 | 10-Q | -12,111,000 | -0.14 | 124,043,000 | 110,915,000 | |
| 2024-09-30 | 10-K | -43,002,000 | -0.52 | 135,567,000 | 120,263,000 | |
| 2024-06-30 | 10-Q | -12,214,000 | -0.14 | 141,535,000 | 129,781,000 | |
| 2024-03-31 | 10-Q | -10,546,000 | -0.13 | 144,516,000 | 134,958,000 | |
| 2023-12-31 | 10-Q | -8,622,000 | -0.11 | 148,070,000 | 135,575,000 | |
| 2023-09-30 | 10-K | -47,505,000 | -0.60 | 154,386,000 | 141,852,000 | |
| 2023-06-30 | 10-Q | -11,280,000 | -0.14 | 157,809,863 | 146,755,000 | |
| 2023-03-31 | 10-Q | -13,107,000 | -0.17 | 159,186,397 | 145,165,000 | |
| 2022-12-31 | 10-Q | -12,972,000 | -0.17 | 148,371,922 | 135,124,000 | |
| 2022-09-30 | 10-K | -47,978,000 | -0.62 | 152,705,000 | 142,491,000 | |
| 2022-06-30 | 10-Q | -12,367,341 | 160,221,144 | 150,736,600 | ||
| 2022-03-31 | 10-Q | -10,437,811 | 160,276,148 | 152,205,041 | ||
| 2021-12-31 | 10-Q | -10,882,367 | 156,896,368 | 146,367,706 | ||
| 2021-09-30 | 10-K | -37,909,000 | -0.54 | 161,616,490 | 150,817,000 | |
| 2021-06-30 | 10-Q | -10,180,141 | 166,419,501 | 157,145,729 | ||
| 2021-03-31 | 10-Q | -8,155,222 | 83,574,238 | 75,810,296 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.